IPO Databook: City Therapeutics (CTY US) - Oct 2026

83 Views11 Oct 2026 12:00

SUMMARY

City Therapeutics, Inc. is a clinical-stage biotechnology company developing RNA interference therapeutics to silence disease-relevant proteins, leveraging its City Platform.
City Therapeutics advanced three programs into or toward the clinic since July 2023, with CITY-FXI Phase 1 data showing 85% FXI knockdown.
The company reported collaboration revenue of $6,358 thousand for six months ended June 30, 2026, alongside a net loss of $(53,443) thousand.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream